These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11549532)

  • 1. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease.
    Dahl R; Greefhorst LA; Nowak D; Nonikov V; Byrne AM; Thomson MH; Till D; Della Cioppa G;
    Am J Respir Crit Care Med; 2001 Sep; 164(5):778-84. PubMed ID: 11549532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease.
    Hogan TJ; Geddes R; Gonzalez ER
    Clin Ther; 2003 Jan; 25(1):285-97. PubMed ID: 12637127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formoterol: a review of its use in chronic obstructive pulmonary disease.
    Cheer SM; Scott LJ
    Am J Respir Med; 2002; 1(4):285-300. PubMed ID: 14720051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is there any difference between effects of ipratropium bromide and formoterol on exercise capacity in moderate COPD patients?
    Akkoca Yildiz O; Onen ZP; Demir G; Eriş Gülbay B; Saryal S; Karabiyikoğlu G
    Tuberk Toraks; 2006; 54(2):105-13. PubMed ID: 16924565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled formoterol versus ipratropium bromide in chronic obstructive pulmonary disease.
    Chhabra SK; Vijayan VK; Vasu T
    Indian J Chest Dis Allied Sci; 2006; 48(2):97-102. PubMed ID: 16696522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study.
    D'Urzo AD; De Salvo MC; Ramirez-Rivera A; Almeida J; Sichletidis L; Rapatz G; Kottakis J;
    Chest; 2001 May; 119(5):1347-56. PubMed ID: 11348938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study.
    Busse W; Levine B; Andriano K; Lavecchia C; Yegen U
    Clin Ther; 2004 Oct; 26(10):1587-98. PubMed ID: 15598475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI.
    Zuwallack R; De Salvo MC; Kaelin T; Bateman ED; Park CS; Abrahams R; Fakih F; Sachs P; Pudi K; Zhao Y; Wood CC;
    Respir Med; 2010 Aug; 104(8):1179-88. PubMed ID: 20172704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial.
    Calverley PM; Kuna P; Monsó E; Costantini M; Petruzzelli S; Sergio F; Varoli G; Papi A; Brusasco V
    Respir Med; 2010 Dec; 104(12):1858-68. PubMed ID: 20965712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dry powder ipratropium bromide is as safe and effective as metered-dose inhaler formulation: a cumulative dose-response study in chronic obstructive pulmonary disease patients.
    Cuvelier A; Muir JF; Benhamou D; Weitzenblum E; Zuck P; Delacenserie R; Taytard A; Iacono P
    Respir Care; 2002 Feb; 47(2):159-66. PubMed ID: 11812272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD.
    Partridge MR; Schuermann W; Beckman O; Persson T; Polanowski T
    Ther Adv Respir Dis; 2009 Aug; 3(4):1-11. PubMed ID: 19734176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.
    Rossi A; Kristufek P; Levine BE; Thomson MH; Till D; Kottakis J; Della Cioppa G;
    Chest; 2002 Apr; 121(4):1058-69. PubMed ID: 11948033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD.
    Liesker JJ; Van De Velde V; Meysman M; Vincken W; Wollmer P; Hansson L; Kerstjens HA; Qvint U; Pauwels RA
    Respir Med; 2002 Aug; 96(8):559-66. PubMed ID: 12195835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
    Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
    Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A; Szalai Z; Pullerits T; Radeczky E
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study.
    Wadbo M; Löfdahl CG; Larsson K; Skoogh BE; Tornling G; Arweström E; Bengtsson T; Ström K;
    Eur Respir J; 2002 Nov; 20(5):1138-46. PubMed ID: 12449166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease.
    Kharidia J; Fogarty CM; Laforce CF; Maier G; Hsu R; Dunnington KM; Curry L; Baumgartner RA; Hanrahan JP
    Pulm Pharmacol Ther; 2008 Aug; 21(4):657-62. PubMed ID: 18501650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study.
    Vogelmeier C; Kardos P; Harari S; Gans SJ; Stenglein S; Thirlwell J
    Respir Med; 2008 Nov; 102(11):1511-20. PubMed ID: 18804362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and tolerability of high-dose formoterol (via Aerolizer) and salbutamol in patients with chronic obstructive pulmonary disease.
    Rosenkranz B; Rouzier R; Kruse M; Dobson C; Ayre G; Horowitz A; Fitoussi S
    Respir Med; 2006 Apr; 100(4):666-72. PubMed ID: 16303295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial.
    Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K
    Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.